Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | EPAS1 | Q99814 | 9/20 | 0.47 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30987223 | 0.75 | MAPT (0.60) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL28563540 | 0.75 | MAPT (0.60) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL4204967 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL329419 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL911402 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL329569 | 0.71 | MAPT (0.61) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL11654916 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL2050847 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL291121 | 0.71 | KDM4E (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL3810651 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026128-A2 | TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-10975071-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190092767-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2019-03-28 | — | — | US | disclosed |
| US-9711734-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-07-18 | — | — | US | disclosed |
| WO-2017015451-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975071-B2 | Inhibitors of KRAS G12C mutant proteins | KRAS, NRAS, HRAS | MAPT 185/4885KDM4E 4115/4885ALDH1A1 3235/4885 |
| US-20190092767-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | MAPT 185/4885KDM4E 4115/4885ALDH1A1 3235/4885 |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | MAPT 4586/4885KDM4E 4383/4885ALDH1A1 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.